Revance Therapeutics, Inc.

Revance Therapeutics, Inc. Class Action Lawsuit Alert: Johnson Fistel Announces Shareholders with Losses Should Contact the Law Firm for More Information

Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Revance Therapeutics, Inc. (NASDAQ: RVNC). The lawsuit seeks to recover losses on behalf of investors who acquired securities between February 29, 2024 and December 6, 2024. Investors have until March 4, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.

If you incurred significant losses and want to act as the lead plaintiff in the Revance Therapeutics class action lawsuit or determine if you are eligible to receive a potential recovery of your losses, please submit your details here:

If you suffered a loss on your investment and would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. The information provided will be held in strict confidence unless and until you authorize us to disclose it.

Name(Required)

First Last

Email(Required)

Phone(Required)

Estimated Losses(Required)

Please provide your statements here

Max. file size: 256 MB.

Where did you see our press release?

News Website

Search Engine

Brokerage Account

Other

Would you like to receive future case and securities updates from Johnson Fistel, LLP via email?(Required)

Yes

Would you like to receive information about Johnson Fistel, LLP's free portfolio monitoring service?(Required)

Yes

Message

By checking the box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Johnson Fistel, LLP, and that submission to or receipt of information from the firm or one of its attorneys via this form, website, email, or telephone does not create an attorney-client relationship.(Required)

I Agree

Contact for More Information: James Baker, (619) 814-4471, jimb@johnsonfistel.com or fjohnson@johnsonfistel.com

The filed complaint alleges that defendants made false statements and/or concealed that: (i) Revance was in material breach of the Distribution Agreement with Teoxane, which granted Revance “the exclusive right to import, market, promote, sell and distribute Teoxane’s line of dermal fillers; (ii) the foregoing subjected the Company to an increased risk of litigation, as well as monetary and reputational harm; (iii) all the foregoing increased the risk that the tender offer would be delayed and/or amended; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Investor Action Steps: Shareholders who incurred losses during the class period, have until March 4, 2025, to move the court to become a lead plaintiff in this action.A lead plaintiff will act on behalf of all other class members in directing the class-action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the class-action lawsuit. An investor’s ability to share any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff.

About Johnson Fistel, LLP | Top Law Firm, Securities Fraud, Investors Rights:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who have purchased on US exchanges. Stay updated with news on stock drops and learn how Johnson Fistel, LLP can help you recover your losses. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com.